Petri Dish

Lab Updates

 

JMCC Paper of the Year 2020

February, 2021

'Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics' chosen as one of the four JMCC papers of the year.

Read More
JMCC.png

Proteoglycans UK Meeting

January 11th, 2021

James presents work from the lab on the role of perlecan in cardiac disease

PG Uk.png

 BSMB 2020

September 11th 2020

Well done to Ben for giving his first online presentation at the British Society of Matrix Biology

Read More
ben_edited_edited_edited.jpg

ISSCR 2020, Virtual

June 24-27th, 2020

Not the trip to Boston we had planned, but well done to Ben and Terri for presenting their first posters at ISSCR.

isscr-2020-virtual-square.png

UEA makes new coronavirus test for hundreds more patients a day

 23 April, 2020 

The Smith Lab was part of a team from Norwich Medical School that set up and performed thousands of additional COVID-19 tests for the NHS

covid.jpg

Successful award of AMS springboard grant 

January 31st, 2020

Springboard offers a bespoke package of support to biomedical researchers at the start of their first independent post to help launch their research careers. This includes funding of up to £100,000 over two years and access to the Academy’s acclaimed mentoring and career development programme.

acm.png

PhD Opportunity 

Deadline 25th November 2019

Using gene editing and pluripotent stem cells to investigate cardiovascular cell signalling
SMITH_U20DTP

JS Project Figure_edited.jpg

11th International Conference on Proteoglycans

October 2nd, 2019

Professor John Whitelock, UNSW, presents our collaborative work in Kanazawa, Japan.

Read More
john.jpg

Ben and Terri join the lab!

October 1st, 2019

The Smith lab welcomes it's first two UEA PhD students!

Read More
Pipetting Samples

PhD opportunity 

April 26, 2019

Engineering mesenchymal stems cells to investigate how they regulate the tumour microenvironment

Closing date 31st May 2019

Start date October 2019

MSCs.jpg

PhD opportunity

 19 February, 2019

By using human induced pluripotent stem cells (hiPSCs) and CRISPR-Cas9 gene editing technology, this PhD project aims to create new human in vitro models of cardiac fibrosis.


Closing date 31st March 2019

Start date October 2019

Fibs.png

Paper Published in Stem Cell Reports

13 November 2018

Hypertrophic cardiomyopathy (HCM) is prevalent and complex, yet treatment options have remained largely static for many years. Existing model systems can suffer from species differences and non-physiological gene expression levels. Here, we developed a human model of HCM by harnessing human induced pluripotent stem cell (hiPSC) reprogramming and CRISPR/Cas9 genome editing technology. By generating hiPSC lines from patients carrying the E99K mutation and a healthy non-carrier relative and then using CRISPR/Cas9 technology, we created a model whereby the mutation had been corrected in two isogenic pairs and introduced in the other. We used these lines to investigate cardiomyocyte function in 3D engineered heart tissues and/or 2D monolayers, measuring contraction, Ca2+ handling and gene expression.


https://doi.org/10.1016/j.stemcr.2018.10.006

Read More
Picture1.jpg